{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:14:00Z","timestamp":1788545640363,"version":"build-2803163510"},"reference-count":16,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Herpes simplex virus (HSV) remains one of the most prevalent sexually transmitted infections worldwide, yet no established pharmacologic pre- or post-exposure prophylaxis strategy currently exists for primary HSV prevention. This study evaluated patient interest in HSV pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) to inform future clinical trial feasibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An anonymous cross-sectional online survey was conducted from August 2025 to April 2026 through outpatient clinics affiliated with an academic medical center, county hospital, and a community-based HIV\/STI organization in Los Angeles, California. Participants were also encouraged to share a public survey link to facilitate broader dissemination. Participants were asked about demographics, sexual practices, STI prevention behaviors, and interest in hypothetical HSV PrEP and HSV PEP strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 89 completed quality controlled surveys suitable for analysis. Participants had a median age of 30 years (range 21\u201376), and the majority identified as cisgender male (65%), white (65%), and HIV-negative (96%). Interest in HSV PEP (75%) exceeded HSV PrEP (54%) across all analyzed groups. Participants currently taking HIV PrEP demonstrated particularly high interest in both HSV PrEP (76%) and HSV PEP (82%). Common barriers included daily medication burden and concerns regarding side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Interest in HSV prophylaxis was observed, particularly among individuals already engaged in STI prevention strategies. These findings support the feasibility of future clinical trials evaluating HSV prophylaxis in high-risk populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09564624261486080","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:28:00Z","timestamp":1788420480000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploratory survey to assess interest in herpes simplex virus pre- and post-exposure prophylaxis"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-3528","authenticated-orcid":false,"given":"Justin Lorence","family":"Wang","sequence":"first","affiliation":[{"name":"University of Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9756-5440","authenticated-orcid":false,"given":"Robert John","family":"Raad","sequence":"additional","affiliation":[{"name":"University of Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7246-8451","authenticated-orcid":false,"given":"Jeremy Joseph","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"University of Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor Mathew","family":"Tierney","sequence":"additional","affiliation":[{"name":"Kansas City Kansas Community College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Dub\u00e9","sequence":"additional","affiliation":[{"name":"University of Southern California"},{"name":"AIDS Healthcare Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saahir","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Veteran Affairs Long Beach Healthcare System, Long Beach, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.19.237149"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01963-9"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142534"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211934"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.JAA.0000937276.51342.74"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000001342"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035144"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.4.3.367"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/JSM.0000000000000255"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/1609406915621420"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011915"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103151"},{"issue":"1","key":"e_1_3_3_15_2","article-title":"Safety and immunogenicity of BNT163, a trivalent mRNA HSV vaccine candidate for genital herpes","volume":"13","author":"Shishido AA","year":"2026","unstructured":"Shishido AA, Tebas P, Crowell CS, et al. Safety and immunogenicity of BNT163, a trivalent mRNA HSV vaccine candidate for genital herpes. Open Forum Infect Dis 2026; 13(Suppl 1): ofaf695.334. https:\/\/doi.org\/10.1093\/ofid\/ofaf695.334","journal-title":"Open Forum Infect Dis"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-019-02462-3"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.420"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624261486080","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624261486080","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624261486080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:53:14Z","timestamp":1788544394000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624261486080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":16,"alternative-id":["10.1177\/09564624261486080"],"URL":"https:\/\/doi.org\/10.1177\/09564624261486080","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"09564624261486080"}}